Capital International LTD Bristol Myers Squibb CO Transaction History

Capital International LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$47.98 - $54.4 $263,266 - $298,492	-5,487 Reduced 2.64%	202,304 $11 Million
Q4 2023 Feb 13, 2024	SELL	$48.48 - $57.85 $259,464 - $309,613	-5,352 Reduced 2.51%	207,791 $10.7 Million
Q3 2023 Nov 13, 2023	BUY	$57.89 - $64.73 $425,433 - $475,700	7,349 Added 3.57%	213,143 $12.4 Million
Q2 2023 Aug 11, 2023	BUY	$63.71 - $70.74 $2.25 Million - $2.5 Million	35,272 Added 20.68%	205,794 $13.2 Million
Q1 2023 May 15, 2023	BUY	$65.71 - $74.53 $2.12 Million - $2.4 Million	32,222 Added 23.3%	170,522 $11.8 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $395,951 - $468,862	5,782 Added 4.36%	138,300 $9.95 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $7,971 - $4.71 Million	61,316 Added 86.12%	132,518 $9.42 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $1.27 Million - $1.4 Million	17,443 Added 32.45%	71,202 $5.48 Million
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $3.31 Million - $3.96 Million	53,759 New	53,759 $3.93 Million

2,457

1.5B

29.6M

32.1M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $116B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Capital International LTD , based on Form 13F filings with the SEC.

Stay updated on Capital International LTD with notifications on news.